Lesser-known GLP-1 medicines span an older daily injection, fresh trial results from China and experimental treatments that could change how often patients inject.
Ozempic has become so familiar that its name can stand in for almost any weight-loss injection. Yet behind that household name is a growing field of medicines with different histories, dosing schedules and ambitions.
Some came before the current excitement. Others are still being tested, with researchers asking whether treatment could involve fewer injections or help tackle complications such as liver disease.
Four names illustrate that changing picture — liraglutide, ribupatide, MariTide and survodutide. Their stories reveal how much the field has evolved, and why a promising weight-loss percentage is only the beginning.
What Do These Medicines Have In Common?
All four act on the receptor for glucagon-like peptide-1, or GLP-1, a gut hormone involved in blood sugar regulation and appetite. Some also target other hormone pathways, making “GLP-1 medicines” shorthand for an increasingly varied group.
These different combinations build on research into how GLP-1, GIP and glucagon influence weight. Scientists are also exploring effects beyond weight management, including changes in cravings and potential benefits for other health conditions.
The evidence is at different stages. Liraglutide has years of clinical use behind it, while newer candidates are working through trials designed to establish their benefits and risks.
Liraglutide Came Before The Weekly Jab
Before weekly injections such as the likes of semaglutide took the world by storm, liraglutide helped establish this approach to treating obesity. Sold under the brand name Saxenda for weight management, it received US Food and Drug Administration approval for adult weight management more than 10 years ago in 2014.
Its daily injection schedule is one immediately obvious difference from weekly treatments. Another is the average weight loss seen in a direct comparison – and these could be the reason why the conversation is dominated by newer molecules.
STEP 8 was a head-to-head clinical trial compared once-weekly subcutaneous semaglutide 2.4 mg directly against once-daily subcutaneous liraglutide 3.0 mg alongside diet and physical activity counselling. At 68 weeks, average weight loss was 6.4% with liraglutide and 15.8% with semaglutide – liraglutide being clearly less effective for weight loss than semaglutide in this trial.
The public conversation around GLP-1 medicines and weight loss may have accelerated in recent years, and liraglutide shows how expectations have changed. A daily injection that helped establish GLP-1 treatment for obesity now sits alongside weekly medicines that can produce greater average weight loss. For patients, both the results and the effort required to maintain treatment matter.
Could MariTide Make Injections Less Frequent?
For someone managing treatment around work, travel and daily life, injection frequency can matter. MariTide, also called maridebart cafraglutide, is being developed with that practical question in mind.
MariTide is an antibody–peptide conjugate. Firstly, it links GLP-1-activating peptides to an antibody that acts on the GIP receptor. This long-acting design supports investigation of monthly or less frequent dosing, potentially reducing the treatment burden associated with weekly medicines.
Receptor-wise, MariTide takes an unusual approach. Like tirzepatide, it targets both the GLP-1 and GIP pathways. But while tirzepatide activates both receptors, MariTide activates GLP-1 receptors and blocks GIP receptors. That makes it an intriguing question for researchers – how can opposite approaches to GIP both help people lose weight?
In a phase 2 trial, participants with obesity without diabetes lost an average of 12.3% to 16.2% of their weight across treatment groups over 52 weeks, compared with 2.5% with placebo.
For patients, MariTide’s clearest potential advantage is fewer injections. If larger trials confirm its benefits and tolerability, monthly dosing could make ongoing treatment easier to fit around everyday life. Its unusual approach to GIP also opens another avenue for developing medicines that act in novel ways on different pathways.
Why Is Survodutide Being Studied For Liver Disease?
Survodutide combines GLP-1 receptor activity with activation of the glucagon receptor. Researchers are investigating it for both obesity and metabolic dysfunction-associated steatohepatitis, or MASH, a form of fatty liver disease involving inflammation and liver cell injury.
Readers may already recognise this direction from semaglutide’s ESSENCE trial, which investigated whether the medicine could improve MASH and liver scarring. Survodutide is exploring a related treatment goal through a different combination of hormone receptors – GLP-1 and glucagon.
Following a phase 2 MASH study, the phase 3 LIVERAGE programme is investigating survodutide in people with MASH and different stages of liver disease, including cirrhosis. These studies will help establish whether its effects translate into meaningful improvements in liver health.
For obesity outcomes, the phase 3 SYNCHRONIZE-1 obesity trial showed average weight loss at 76 weeks was 12.2% and 13.0% with the two survodutide doses, compared with 5.4% with placebo. Its liver research asks a further question. Can treatment improve disease in people who already have liver scarring?
Ribupatide Brings Fresh Results From China
Ribupatide has a timely reason to enter the conversation. Its phase 3 GEMINI-1 results appeared in JAMA on 15 November 2026. The weekly injection activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. The study involved 567 adults in China with overweight or obesity, without diabetes.
After 48 weeks, average weight reductions were 10.7%, 16.4% and 17.7% with the three ribupatide doses, compared with 1.4% with placebo. Participants also received lifestyle support.
For Asian readers, the trial provides evidence from a Chinese population, on top of the SURMOUNT-CN trial with tirzepatide, which works similarly on the GLP-1 and GIP receptors. Ribupatide could eventually offer another treatment option using the same broad approach as tirzepatide. Beyond that, what remains unanswered is whether ribupatide will eventually offer significant advantages in tolerability, affordability or access on top of efficacy – factors that will matter to patients as much as the number on the scales.

Which development would you most like to see – different hormone pathways, fewer injections, more affordable treatment, better efficacy, or benefits beyond weight loss? As research opens up more possibilities, what would make the biggest difference to you?
